Bladder cancer trials in Spain

In Spain 59 Also abroad 625

59 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in Spain
Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma
Where
A Coruña, Badalona, Barcelona, Bilbao, Cartagena, Ciudad Real, Girona, Granada, Jerez de la Frontera, Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, Madrid, Murcia, Palma, Pamplona, Sabadell, Salamanca, Santander, Santiago De Compostela, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
196 worldwide
Run by
European Uro-Oncology Group Stichting
See details and how to joinNCT02969083 · EU 2024-514991-41-01
Phase 1Taking people
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
124 worldwide
Run by
Pliant Therapeutics, Inc.
See details and how to joinNCT06270706
Phase 1/2Taking people
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Where
Barcelona, Madrid
Age
18 years and over
People
55 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Where
Las Palmas de Gran Canaria, Madrid, Pozuelo de Alarcón, Sabadell, Sevilla
Age
18 years and over
People
308 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06833073 · EU 2024-517335-46-00
Phase 3Taking people
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
Where
Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Santander, Sevilla
Age
18 years to 64 years
People
262 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525030-57-00 · EU 2025-525030-57-00
Phase 2Taking people
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Where
Elche, Granada, Las Palmas de Gran Canaria, L'hospitalet De Llobregat, Madrid, Ourense, Oviedo, Pamplona, Sevilla, Valencia
Age
18 years and over
People
88 worldwide
Run by
Astellas Pharma Global Development Inc.
See details and how to join2025-524488-18-00 · EU 2025-524488-18-00
Phase 4Taking people
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants With Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (LG-IR-NMIBC) From Study BL013
Where
Madrid
Age
18 years and over
People
33 worldwide
Run by
Urogen Pharma Ltd.
See details and how to join2026-526359-75-00 · EU 2026-526359-75-00
Phase 1/2Taking people
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Where
Barcelona
Age
18 years and over
People
20 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06668493 · EU 2024-514360-70-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Barcelona, Girona, Madrid, Marbella, Santiago De Compostela, Valencia
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 3Taking people
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Where
A Coruña, Barcelona, Cadiz, Córdoba, Madrid, Murcia, Seville, Valencia
Age
18 years and over
People
70 worldwide
Run by
UroGen Pharma Ltd.
See details and how to joinNCT06774131 · EU 2024-519343-15-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Barcelona, Girona, Madrid, Majadahonda, Palma, Pamplona, Pozuelo de Alarcón, Sabadell, Salamanca, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Badalona, Barcelona, Madrid, Málaga, Pamplona
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 1/2Taking people
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Where
Badalona, Barcelona, L'hospitalet De Llobregat, Madrid, Murcia, Pozuelo de Alarcón, San Sebastián de los Reyes, Santander
Age
18 years and over
People
350 worldwide
Run by
enGene, Inc.
See details and how to joinNCT04752722 · EU 2024-512900-20-00
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Badajoz, Barcelona, Córdoba, Madrid, Santander, Seville, Valencia
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Barcelona, Madrid, Santiago de Compostela, Sevilla, Valencia
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 2Not yet taking people in Spain
Genitourinary Tumors With Sacituzumab Tirumotecan
Where
Madrid
Age
18 years and over
People
100
Run by
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
See details and how to joinNCT07716917 · EU 2026-526048-10-00
Phase 2Taking people
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Where
Badalona, Barcelona, Madrid, Sabadell, Santander, Sevilla
Age
18 years and over
People
372 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04879329 · EU 2022-500030-28-01
Phase 3Taking people
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Where
Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Santander, Seville
Age
18 years and over
People
915 worldwide
Run by
AstraZeneca
See details and how to joinNCT07720284
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Barcelona, Elche, Jerez de la Frontera, Madrid, Málaga, Santander
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00
Phase 1/2Taking people
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Where
Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia
Age
18 years and over
People
180 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00
Phase 1Taking people
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
Where
Badalona, L'hospitalet De Llobregat
Age
18 years and over
People
44
Run by
Laboratorio Reig Jofre S.A.
See details and how to join2026-525897-20-00 · EU 2026-525897-20-00